Zurich  — Novartis will cut 2,550 jobs in Switzerland and Britain over four years, it said on Tuesday, as the Swiss drugmaker strives to boost profit and focus on new medicines. Switzerland will bear the brunt, with 2,150 cuts planned at four factories and its Swiss-based business services unit. About 400 jobs will also go in Grimsby, northeast England, where the company will close a plant that makes pills. Novartis  employs about  124,000 people worldwide. But following the planned spin-off of eyecare unit Alcon in early 2019, that would  fall to fewer than 100,000 people by 2022, CEO   Vas Narasimhan said. Novartis's network of 66 global factories is operating below capacity after the expiry of patents on high-volume pills such as Diovan for heart disease, he added. As the company shifts to gene therapies and biologics such as arthritis treatment Cosentyx, Narasimhan said the cuts were needed to help him boost the drugs unit's operating margin to about 35%  of sales, what he calls...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.



Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now